[Use of acetylcholinesterase inhibitors and memantine in Alzheimer-type dementia].

نویسندگان

  • Manuel Portela Romero
  • Julio Pombo Romero
  • Rosendo Bugarín González
  • Margarita Tasende Souto
  • Silvia Represa Veiga
چکیده

BACKGROUND The therapeutic options to treat Alzheimer-type dementia (ATD) in recent years, have made it increasingly necessary to become familiar with the employment pattern of these new medicinal products. METHODS A cross-sectional observational study of the population with ATD treated with acetylcholinesterase inhibitors and/or memantine in the Gallician Health Service. Databases were compiled with the demographic variables and use data during April 2005 of the medicinal products studied. RESULTS Of the 5110 patients with ATD, 70.47% were women. The mean age of the women was 80.12 and of the men was 78.61 years old, with standard deviations of 6.66 and 7.03, respectively. The female sex was one of the factors associated with presenting ATD to pharmacological treatment (OR: 1.932 [CI 95%: 1.819-2.052]). The medication used most was donepezyl (44.46% of patients). Significant differences were found in that memantine was used to treat more patients in the group of patients < or =64 years (19.7% in < or =64 years vs. 14% in >64 years [p < 0.05]), and donepezyl was preferentially used in patients > or =95 years (75% in > or =95 years vs. 46.9% in <95 years [p < 0.03]). No significant differences were observed in the use of anti-dementia therapy, expressed in DDD/patient/day between the sexes, age groups, or in the age groups separated according to sex. CONCLUSIONS The use of memantine (in monotherapy or in combination) is more frequent in patients under 64 years old. Female sex was found to be a factor associated with presenting ATD to pharmacological treatment.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Treatment of Alzheimer disease.

Alzheimer disease is the most common form of dementia, affecting nearly one-half [corrected] of Americans older than 85 years. It is characterized by progressive memory loss and cognitive decline. Amyloid plaque accumulation, neurofibrillary tau tangles, and depletion of acetylcholine are among the pathologic manifestations of Alzheimer disease. Although there are no proven modalities for preve...

متن کامل

NeuroImmune Mechanisms in Alzheimer’s Disease

Senile dementia of the Alzheimer type (sDAT) is a progressive disease of the brain that afflicts primarily the elderly. Patients with sDAT lose cognitive, intellectual, functional, and social abilities, and become fully dependent upon their caregiver. As the “baby boomer” generation advances in age, it is predicted that by the end of the decade, over 7.5-10 million people will be diagnosed with...

متن کامل

2-(2-(4-Benzoylpiperazin-1-yl)ethyl)isoindoline-1,3-dione derivatives: Synthesis, docking and acetylcholinesterase inhibitory evaluation as anti-alzheimer agents

Objective(s): Alzheimer’s disease (AD) as progressive cognitive decline and the most common form of dementia is due to degeneration of the cholinergic neurons in the brain. Therefore, administration of the acetylcholinesterase (AChE) inhibitors such as donepezil is the first choice for treatment of the AD. In the present study, we focused on the synthesis and anti-cholinesterase evaluation of n...

متن کامل

Submission on Behalf of the British Geriatrics Society to the National Institute for Clinical Excellence Health Technology Appraisal: Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease

Alzheimer’s disease (AD) is the most common cause of dementia and is a progressive neurodegenerative illness for which at present there is no cure. The management involves both nonpharmacological and pharmacological approaches. This submission will concentrate mostly on the acetylcholinesterase inhibitors (AChEI), donepezil, rivastigmine and galantamine as well as the NMDA receptor antagonist m...

متن کامل

Isolation and characterization of compounds from Nardostachys jatamansi targeting acetylcholinesterase inhibitors based on TLC-bioautography

Background and objectives: The cholinergic deficit correlates with the severity of Alzheimer’s disease. The cholinergic function can be improved by AChE inhibitors blocking this key enzyme in the breakdown of acetylcholine. Based on traditional medicine, during two last decades the use of herbal medicinal substances in dementia therapy has been studied. Nardostachys jataman...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Revista espanola de salud publica

دوره 79 6  شماره 

صفحات  -

تاریخ انتشار 2005